Neogenomics (NEO) Notes Payables (2024 - 2025)

Neogenomics' (NEO) quarterly Notes Payables came in at $201.1 million in Q1 2025, little changed on a QoQ basis from $200.8 million in Q4 2024.

Neogenomics (NEO) Notes Payables (2024 - 2025) Analysis & Trends

Neogenomics (NEO) has 2 years of Notes Payables data on file, last reported at $201.1 million in Q1 2025.

Quarterly Notes Payables changed N/A year-over-year to $201.1 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $201.1 million (changed N/A YoY) and the FY2024 annual result came in at $200.8 million, changed N/A from the prior year.
Notes Payables held at $201.1 million in Q1 2025, from $200.8 million in the prior quarter.
In the past five years, Notes Payables ranged from a high of $201.1 million in Q1 2025 to a low of $200.1 million in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Thermo Fisher Scientific	213.40 Bn	209.33 Bn	8.34 Bn
2	Danaher	139.94 Bn	135.59 Bn	3.61 Bn
3	Idexx Laboratories	46.03 Bn	45.83 Bn	779.09 Mn
4	Agilent Technologies	39.69 Bn	37.88 Bn	990.00 Mn
5	Iqvia Holdings	39.32 Bn	37.24 Bn	1.44 Bn
6	Natera	38.47 Bn	37.37 Bn	696.04 Mn
7	Illumina	29.98 Bn	28.82 Bn	770.00 Mn
8	Mettler Toledo International	28.57 Bn	28.52 Bn	650.22 Mn
9	Quest Diagnostics	26.21 Bn	25.58 Bn	1.03 Bn
10	Neogenomics	2.04 Bn	1.90 Bn	91.88 Mn

Download Data